236 related articles for article (PubMed ID: 15240516)
1. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
2. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S; Mannarino O; McDowell HP; Pauser U; Vitali R; Natali PG; Altavista P; Andreano T; Coco S; Boldrini R; Bosco S; Clerico A; Cozzi D; Donfrancesco A; Inserra A; Kokai G; Losty PD; Nicotra MR; Raschellà G; Tonini GP; Dominici C
Clin Cancer Res; 2005 Jan; 11(1):380-9. PubMed ID: 15671569
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
[TBL] [Abstract][Full Text] [Related]
5. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
Henrich KO; Fischer M; Mertens D; Benner A; Wiedemeyer R; Brors B; Oberthuer A; Berthold F; Wei JS; Khan J; Schwab M; Westermann F
Clin Cancer Res; 2006 Jan; 12(1):131-8. PubMed ID: 16397034
[TBL] [Abstract][Full Text] [Related]
7. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
8. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
Doolan P; Clynes M; Kennedy S; Mehta JP; Crown J; O'Driscoll L
Breast Cancer Res Treat; 2008 May; 109(2):359-65. PubMed ID: 17624586
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
11. Implications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progression.
Ngan ES; Sit FY; Lee K; Miao X; Yuan Z; Wang W; Nicholls JM; Wong KK; Garcia-Barcelo M; Lui VC; Tam PK
Clin Cancer Res; 2007 Feb; 13(3):868-75. PubMed ID: 17289879
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer testis antigens in head and neck squamous cell carcinomas.
Figueiredo DL; Mamede RC; Proto-Siqueira R; Neder L; Silva WA; Zago MA
Head Neck; 2006 Jul; 28(7):614-9. PubMed ID: 16475205
[TBL] [Abstract][Full Text] [Related]
14. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
15. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses.
Beierle EA; Massoll NA; Hartwich J; Kurenova EV; Golubovskaya VM; Cance WG; McGrady P; London WB
Clin Cancer Res; 2008 Jun; 14(11):3299-305. PubMed ID: 18519756
[TBL] [Abstract][Full Text] [Related]
17. [Detection of MYCN mRNA in neuroblastoma cell lines by quantitative RT-PCR].
Feng C; Tang SQ; Wang JW; Liu LZ; Gao XN; Long H
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):47-50. PubMed ID: 17306077
[TBL] [Abstract][Full Text] [Related]
18. Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma.
Voth H; Oberthuer A; Simon T; Kahlert Y; Berthold F; Fischer M
Mol Cancer Res; 2007 Dec; 5(12):1276-84. PubMed ID: 18171985
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]